Seers Technology (458870) Wins FDA Clearance, Sparking Global Expansion and Re-rating Potential

Source Fact: Mirae Asset Securities / 2026.06.29

Investment Opinion & Target Price: No specific opinion provided / Current price is at a 12-month forward P/E of 22x, representing an undervaluation compared to the global peer average (23x) and the company’s previous peak (37x)

Key Momentum: Relief of uncertainties regarding overseas business and realization of entry into the U.S. market through the FDA 510(k) clearance of the wearable ECG monitor “mobiCARE”

📊 1. [Valuation Metrics and Investment Indicators Analysis]

• The current stock price is at a 12-month forward P/E of 22x, which is similar to the 1-year average (22x).
• It is considered undervalued compared to the global peer average of 23x and the previous peak of 37x.
• As a Track A investment candidate for the National Growth Fund, the company has secured a strong justification for expansion into the Middle East and the U.S. following this FDA clearance.

🚀 2. [Market Opportunity and Key Achievements]

• FDA Clearance Achievement: On June 25, the company received FDA 510(k) clearance for its wearable ECG monitor, “mobiCARE”.
• Clinical Data Competitiveness: The company secured clinical trial data proving that “mobiCARE” is equivalent to industry-standard equipment, marking an industry first alongside Philips’ IntelliVue MX40.
• Future Outlook:
  • The original target for U.S. entry was H1–Q3 2027, but there is sufficient potential for the schedule to be accelerated.
  • Faster progress is expected compared to competitors, supported by clinical data obtained during the FDA’s request for additional information.
  • Key upcoming events: Confirmation of domestic market dominance through the Q2 2026 earnings release and the shipment of initial supplies to the Middle East.

📝 Editor’s Comment (by K-STOCK Editor)

Despite its outstanding performance in the domestic market, Seers has suffered from unnecessary noise regarding overseas business uncertainties due to the lack of FDA clearance. This FDA 510(k) clearance is significant not just as a regulatory approval, but as the establishment of a bridgehead for entry into the U.S. market. In particular, the clinical data proving equivalence to global standard equipment is a key asset that solidifies the company’s technical entry barriers. As the justification for expansion into the dual markets of the Middle East and the U.S. has been strengthened, the current valuation level is judged to be in an undervalued range that does not fully reflect the company’s growth potential.

📢 Disclaimer and Source Notice Source: This content is structured and rewritten based on the financial facts and numerical data from the officially disclosed securities report

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. It does not constitute financial advice or a recommendation to buy/sell any specific stock under any circumstances. All investment decisions and financial responsibilities rest solely with the investor.

Contact: For compliance or copyright inquiries, please contact ksb220805@gmail.com.